US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
The demand in Africa for COVID-19 vaccines has declined
Global Phase-3 study initiation expected in the second half of 2024
CHL is strengthening its play in the fast-growing beauty and personal care sector
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
KRKA holds 51% and Laurus Labs holds 49% shareholding
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Subscribe To Our Newsletter & Stay Updated
